Takeda's Once-Daily Psoriasis Pill Hits 70 Percent Clear Skin in Phase 3 Trials

For the roughly 8 million Americans managing plaque psoriasis, the treatment calculus has always involved a trade-off: take a convenient pill with modest results, or commit to injections that clear skin more reliably. New Phase 3 data from Takeda may be about to collapse that gap entirely. Zasocitinib, a once-daily oral TYK2 inhibitor, delivered approximately 70 percent clear or almost-clear skin across two large-scale trials presented at the American Academy of Dermatology annual meeting in Denver. The results position the drug as the most effective oral psoriasis therapy tested to date — and Takeda is preparing to file for FDA approval this year. ## What the Trials Found The LATITUDE program enrolled 1,801 adults with moderate-to-severe plaque psoriasis across 21 countries. Both trials — PsO-3001 (693 patients) and PsO-3002 (1,108 patients) — were randomized, double-blind, and included both placebo and apremilast as comparators. At week 16, zasocitinib achieved sPGA 0/1 (clear or almost-clear skin) in 71.4 percent of patients in Study 3001 and 69.2 percent in Study 3002. By comparison, placebo hovered around 11 percent and apremilast — the current go-to oral option — reached roughly 31 percent. Complete skin clearance (PASI 100) was observed in a third of patients in Study 3001 and a quarter in Study 3002, rates that begin to approach what injectable biologics achieve. Responses continued to deepen through week 24 and held through week 60, with over 90 percent of responders maintaining their results at that extended timepoint. ## Why TYK2 Selectivity Matters Zasocitinib belongs to the TYK2 inhibitor class, but Takeda engineered it for extreme precision. The molecule demonstrates over one-million-fold selectivity for TYK2 compared to JAK1, JAK2, and JAK3 — enzymes whose inhibition has historically raised safety concerns around blood counts, cholesterol, and cardiovascular events in older JAK inhibitors. By maintaining 24-hour suppression of IL-23 and other inflammatory pathways through TYK2 alone, zasocitinib aims to deliver biologic-level efficacy without the broad immunosuppression that made earlier JAK drugs controversial. In these trials, the most common adverse events were upper respiratory tract infections (10.1 percent), nasopharyngitis (6.2 percent), and acne (6.5 percent). ## Where This Fits in the Treatment Landscape Currently, people with moderate-to-severe psoriasis face a tiered treatment path. Topicals and phototherapy come first. When those fall short, systemic options include oral medications like apremilast and deucravacitinib (Bristol Myers Squibb's Sotyktu, the first approved TYK2 inhibitor), or injectable biologics targeting IL-17, IL-23, or TNF-alpha. Biologics remain the most effective class, but they require regular injections, cold-chain storage, and often prior authorization battles with insurers. Oral options have been easier to access but harder to justify on efficacy — until now. Zasocitinib's 70 percent sPGA 0/1 rate at week 16 substantially outperforms apremilast (roughly 31 percent in these same trials) and appears to exceed published deucravacitinib data, though a direct head-to-head comparison is still underway. If the NDA filing proceeds on schedule later this year, approval could come in 2027.